{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T11:11:50Z","timestamp":1770462710707,"version":"3.49.0"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.cyto.2022.156007","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T17:52:38Z","timestamp":1660672358000},"page":"156007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Immune hallmarks of rheumatoid arthritis management: A brief review"],"prefix":"10.1016","volume":"158","author":[{"given":"Rephany","family":"Fonseca Peixoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Ewerton Maia Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Henrique de Sousa Palmeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"C\u00e9zar Comberlang Queiroz Davis dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatjana","family":"Keesen de Souza Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"de Sousa Braz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2022.156007_b0005","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10067-015-3015-x","article-title":"Rheumatoid arthritis in Latin America: the importance of an early diagnosis","volume":"34","author":"Da Mota","year":"2015","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.cyto.2022.156007_b0015","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-017-0635-y","article-title":"The Multifunctional Role of the Chemokine System in Arthritogenic Processes","volume":"19","author":"Bernardini","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"issue":"13","key":"10.1016\/j.cyto.2022.156007_b0020","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cyto.2022.156007_b0025","first-page":"315","article-title":"Immunopathogenesis of alphaviruses","author":"Baxter","year":"2020","journal-title":"Immunopathology"},{"issue":"4","key":"10.1016\/j.cyto.2022.156007_b0030","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.rdc.2017.06.005","article-title":"Neurologic manifestations of rheumatoid arthritis","volume":"43","author":"Dequattro","year":"2017","journal-title":"Rheum. Dis. Clin."},{"issue":"5","key":"10.1016\/j.cyto.2022.156007_b0035","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jemermed.2018.07.030","article-title":"Emergent complications of rheumatoid arthritis","volume":"55","author":"Berman","year":"2018","journal-title":"J. Emerg. Med."},{"issue":"2","key":"10.1016\/j.cyto.2022.156007_b0040","first-page":"243","article-title":"Skin manifestations of rheumatoid arthritis","volume":"153","author":"Lora","year":"2018","journal-title":"Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia"},{"key":"10.1016\/j.cyto.2022.156007_b0045","article-title":"Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout","author":"Hansildaar","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.berh.2017.08.003","article-title":"Genetic and environmental risk factors for rheumatoid arthritis","volume":"31","author":"Deane","year":"2017","journal-title":"Best Practice Res. Clin. Rheumatol."},{"issue":"10","key":"10.1016\/j.cyto.2022.156007_b0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3390\/cells7100161","article-title":"Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development","volume":"7","author":"Yap","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.cyto.2022.156007_b0060","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019shea","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.cyto.2022.156007_b0065","doi-asserted-by":"crossref","unstructured":"J.F. Smolen, D. Aletaha, l.B. McInnes, Seminar: Rheumatoid arthritis, The Lancet 388(10055) (2016) 2023-2038.","DOI":"10.1016\/S0140-6736(16)30173-8"},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0070","first-page":"2","article-title":"Recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis","volume":"58","author":"Marques","year":"2017","journal-title":"Adv. Rheumatol."},{"issue":"7","key":"10.1016\/j.cyto.2022.156007_b0075","doi-asserted-by":"crossref","first-page":"10018","DOI":"10.1002\/jcp.27860","article-title":"Strategies toward rheumatoid arthritis therapy; the old and the new","volume":"234","author":"Abbasi","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.cyto.2022.156007_b0080","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2022.156007_b0085","series-title":"Seminars in immunopathology","first-page":"437","article-title":"The role of autoantibodies in the pathophysiology of rheumatoid arthritis","author":"Derksen","year":"2017"},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0090","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nri.2016.124","article-title":"The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting","volume":"17","author":"Malmstrom","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2022.156007_b0095","doi-asserted-by":"crossref","first-page":"101438","DOI":"10.1016\/j.berh.2019.101438","article-title":"How to investigate: Pre-clinical rheumatoid arthritis","volume":"33","author":"Martins","year":"2019","journal-title":"Best Practice Res. Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0100","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/imr.12829","article-title":"Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology","volume":"294","author":"Volkov","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cyto.2022.156007_b0105","doi-asserted-by":"crossref","unstructured":"C.M. Weyand, J.J. Goronzy, The immunology of rheumatoid arthritis, Nat. Immunol. 22 (2021) 10\u201318 10.1038\/s41590-020-00816-x.","DOI":"10.1038\/s41590-020-00816-x"},{"issue":"23","key":"10.1016\/j.cyto.2022.156007_b0110","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/art.39811","article-title":"Altered Innate Lymphoid Cell Subsets in Human Lymph Node Biopsy Specimens Obtained During the At-Risk and Earliest Phases of Rheumatoid Arthritis","volume":"69","author":"Rodr\u0131guez-Carrio","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cyto.2022.156007_b0120","doi-asserted-by":"crossref","first-page":"104263","DOI":"10.1016\/j.cellimm.2020.104263","article-title":"Type 1 helper T cells generate CXCL9\/10-producing T-bet+ effector B cells potentially involved in the pathogenesis of rheumatoid arthritis","volume":"360","author":"Nakayama","year":"2021","journal-title":"Cell. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2022.156007_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.145217","article-title":"Shared recognition of citrullinated tenascin-C peptides by T and B cells in rheumatoid arthritis","volume":"6","author":"Song","year":"2021","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.cyto.2022.156007_b0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/1756-185X.12211","article-title":"A study on relationship among apoptosis rates, number of peripheral T cell subtypes and disease activity in rheumatoid arthritis","volume":"19","author":"Ji","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.cyto.2022.156007_b0135","series-title":"Seminars in immunopathology","first-page":"365","article-title":"Selected cytokine pathways in rheumatoid arthritis","author":"Noack","year":"2017"},{"key":"10.1016\/j.cyto.2022.156007_b0140","series-title":"Co-signal Molecules in T Cell Activation","first-page":"153","article-title":"Role of Co-stimulatory Molecules in T Helper Cell Differentiation","author":"Schorer","year":"2019"},{"key":"10.1016\/j.cyto.2022.156007_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/1915068","article-title":"Dysregulation of Innate Lymphoid Cells in Patients with Active Rheumatoid Arthritis and Mice with Collagen-Induced Arthritis","volume":"2021","author":"Yang","year":"2021","journal-title":"Mediators Inflamm."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-020-2115-4","article-title":"Innate lymphoid cells in inflammatory arthritis","volume":"22","author":"Fang","year":"2020","journal-title":"Arthrit. Res. Therapy"},{"issue":"584116","key":"10.1016\/j.cyto.2022.156007_b0155","first-page":"1","article-title":"Rheumatoid Arthritis Synovial Fluid Neutrophils Drive Inflammation Through Production of Chemokines, Reactive Oxygen Species, and Neutrophil Extracellular Traps","volume":"11","author":"Wright","year":"2021","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.cyto.2022.156007_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.139388","article-title":"Neutrophil extracellular traps mediate articular cartilage damage and enhance cartilage component immunogenicity in rheumatoid arthritis","volume":"5","author":"Carmona-Rivera","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.cyto.2022.156007_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2020.102484","article-title":"Autoantibodies to neutrophil extracellular traps represent a potential serological biomarker in rheumatoid arthritis","volume":"113","author":"de Bont","year":"2020","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.cyto.2022.156007_b0170","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bj.2020.06.010","article-title":"Innate immunity drives pathogenesis of rheumatoid arthritis","volume":"44","author":"Edilova","year":"2021","journal-title":"Biomed. J."},{"issue":"9","key":"10.1016\/j.cyto.2022.156007_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162306","article-title":"The proportion of regulatory T cells in patients with rheumatoid arthritis: a meta-analysis","volume":"11","author":"Morita","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2022.156007_b0180","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fimmu.2019.00353","article-title":"Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation\u2014Lessons from Rheumatoid Arthritis","volume":"10","author":"Chemin","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12016-015-8520-9","article-title":"A comprehensive review of inflammatory cell migration in rheumatoid arthritis","volume":"51","author":"Nevius","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0190","first-page":"1","article-title":"B cells inhibit bone formation in rheumatoid arthritis by suppressing osteoblast differentiation","volume":"9","author":"Wen","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cyto.2022.156007_b0195","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.intimp.2019.03.008","article-title":"T-cells interact with B cells, dendritic cells, and fibroblast-like synoviocytes as hub-like key cells in rheumatoid arthritis","volume":"70","author":"Hu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2022.156007_b0200","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.intimp.2018.12.007","article-title":"Regulatory B cells in inflammatory diseases and tumor","volume":"67","author":"Cai","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2022.156007_b0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cca.2016.02.010","article-title":"Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis","volume":"455","author":"Mateen","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cyto.2022.156007_b0210","series-title":"Seminars in immunopathology","first-page":"385","article-title":"Synovial cellular and molecular markers in rheumatoid arthritis","author":"Amin","year":"2017"},{"issue":"8","key":"10.1016\/j.cyto.2022.156007_b0215","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","article-title":"Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions","volume":"75","author":"Georg","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.cyto.2022.156007_b0220","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/NHH.0000000000000203","article-title":"Methotrexate","volume":"33","author":"Mager","year":"2015","journal-title":"Home Healthcare Now"},{"key":"10.1016\/j.cyto.2022.156007_b0225","first-page":"8","article-title":"Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis","author":"Hazlewood","year":"2016","journal-title":"Cochrane Database System. Rev."},{"key":"10.1016\/j.cyto.2022.156007_b0230","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review","volume":"158","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.cyto.2022.156007_b0235","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11302-016-9529-0","article-title":"Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression","volume":"12","author":"De Oliveira","year":"2016","journal-title":"Purinergic Signalling"},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0240","article-title":"Phenotypical analysis of ectoenzymes CD39\/CD73 and adenosine receptor 2A in CD4+ CD25highFoxp3+ regulatory T-cells in psoriasis","volume":"59","author":"Ling","year":"2018","journal-title":"Australas. J. Dermatol."},{"issue":"2","key":"10.1016\/j.cyto.2022.156007_b0245","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11302-016-9505-8","article-title":"Methotrexate up-regulates ecto-5\u2032-nucleotidase\/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment","volume":"12","author":"Fabr\u00edcio","year":"2016","journal-title":"Purinergic Signall."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0250","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrrheum.2016.178","article-title":"Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases","volume":"13","author":"Crostein","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"20","key":"10.1016\/j.cyto.2022.156007_b0255","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.3390\/ijms20205023","article-title":"Methotrexate an old drug with new tricks","volume":"20","author":"Yosra","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2022.156007_b0260","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3389\/fimmu.2018.02228","article-title":"Sinomenine inhibits the progression of rheumatoid arthritis by regulating the secretion of inflammatory cytokines and monocyte\/macrophage subsets","volume":"9","author":"Liu","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2022.156007_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-018-1554-7","article-title":"Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1\u03b2 on rheumatoid arthritis fibroblast-like synoviocytes","volume":"20","author":"Bergstrom","year":"2018","journal-title":"Arthritis Res. Therapy"},{"issue":"18","key":"10.1016\/j.cyto.2022.156007_b0270","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.3390\/ijms21186847","article-title":"Methrotexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Na\u00efve Rheumatoid Arthritis Patients","volume":"21","author":"Sanz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.cyto.2022.156007_b0275","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.5114\/aoms.2018.79485","article-title":"Modulator role of infliximab and methotrexate through the transient receptor potential melastatin 2 (TRPM2) channels in neutrophils of patients with rheumatoid arthritis: a pilot study","volume":"15","author":"Dogru","year":"2019","journal-title":"Arch. Med. Sci.: AMS"},{"key":"10.1016\/j.cyto.2022.156007_b0280","doi-asserted-by":"crossref","unstructured":"M. Chen, K.A. Daddy JC, Z. Su, et al., Folate Receptor-Targeting and Reactive Oxygen Species-Responsive Liposomal Formulation of Methotrexate for Treatment of Rheumatoid Arthritis, Pharmaceutics 11 (11) (2019) 582. 10.3390\/pharmaceutics11110582.","DOI":"10.3390\/pharmaceutics11110582"},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0285","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/rheumatology\/keu279","article-title":"Methotrexate-mediated inhibition of nuclear factor \u03baB activation by distinct pathways in T cells and fibroblast-like synoviocytes","volume":"54","author":"Spurlock","year":"2015","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.cyto.2022.156007_b0290","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1586\/17512433.2015.1019343","article-title":"Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases","volume":"8","author":"Fragoso","year":"2015","journal-title":"Exp. Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0295","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12891-017-1673-3","article-title":"Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial","volume":"18","author":"Wijesinghe","year":"2017","journal-title":"BMC Musculoskel. Disord."},{"issue":"6","key":"10.1016\/j.cyto.2022.156007_b0300","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000493390","article-title":"Rheumatoid arthritis: a brief overview of the treatment","volume":"27","author":"Bullock","year":"2018","journal-title":"Med. Princ. Pract."},{"issue":"4","key":"10.1016\/j.cyto.2022.156007_b0305","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/intimm\/dxw006","article-title":"CD4+ T-cell subsets in inflammatory diseases: beyond the T h 1\/T h 2 paradigm","volume":"28","author":"Hirahara","year":"2016","journal-title":"Int. Immunol."},{"issue":"11","key":"10.1016\/j.cyto.2022.156007_b0310","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3390\/molecules21111565","article-title":"Circulating IL-27 is elevated in rheumatoid arthritis patients","volume":"21","author":"Lai","year":"2016","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0315","first-page":"1","article-title":"IL-22-producing CD4+ T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide","volume":"7","author":"Zhong","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-12163-z","article-title":"HIF1\u03b1 inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis","volume":"10","author":"Liang","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.cyto.2022.156007_b0325","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12328-019-00954-2","article-title":"Leflunomide-induced colitis in association with enterocutaneous fistula in an immunosuppressed patient with renal transplant and rheumatoid arthritis","volume":"12","author":"Kwok","year":"2019","journal-title":"Clin. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.cyto.2022.156007_b0330","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10238-018-0500-y","article-title":"Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis","volume":"18","author":"Costa","year":"2018","journal-title":"Clin. Exp. Med."},{"issue":"2","key":"10.1016\/j.cyto.2022.156007_b0335","first-page":"S1","article-title":"Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis","volume":"2","author":"Choy","year":"2017","journal-title":"J. Sclerod. Rel. Disord."},{"issue":"7","key":"10.1016\/j.cyto.2022.156007_b0340","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2017.83","article-title":"The role of IL-6 in host defence against infections: immunobiology and clinical implications","volume":"13","author":"Rose-John","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"12","key":"10.1016\/j.cyto.2022.156007_b0345","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0350","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.aller.2013.11.003","article-title":"Inflammatory markers in patients with rheumatoid arthritis","volume":"43","author":"Shrivastava","year":"2015","journal-title":"Allergol. Immunopathol."},{"key":"10.1016\/j.cyto.2022.156007_b0355","doi-asserted-by":"crossref","unstructured":"C. Diaz-Torne, P. Moya, M.V. Hernandez, et al. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. In: Seminars in arthritis and rheumatism, WB Saunders (2018) 757-764. 10.1016\/j.semarthrit.2017.10.022.","DOI":"10.1016\/j.semarthrit.2017.10.022"},{"issue":"5","key":"10.1016\/j.cyto.2022.156007_b0360","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12272-015-0569-8","article-title":"IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future","volume":"38","author":"Kim","year":"2015","journal-title":"Arch. Pharmacal Res."},{"issue":"2","key":"10.1016\/j.cyto.2022.156007_b0365","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/14397595.2018.1546357","article-title":"IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review","volume":"29","author":"Ogata","year":"2019","journal-title":"Mod. Rheumatol."},{"issue":"17","key":"10.1016\/j.cyto.2022.156007_b0370","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.cyto.2022.156007_b0375","first-page":"1","article-title":"Peripheral blood CD4 CD25 CD127 [low] regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response","volume":"17","author":"Kikuchi","year":"2015","journal-title":"Arthrit. Res. Therapy"},{"issue":"2","key":"10.1016\/j.cyto.2022.156007_b0380","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/art.38246","article-title":"Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis","volume":"66","author":"Thiolat","year":"2014","journal-title":"Arthrit. Rheumatol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0385","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cyto.2022.156007_b0390","doi-asserted-by":"crossref","unstructured":"S.T. Wei, Y.H. Sun, S.H. Zong, Y.B. Xiang, Serum levels of IL-6 and TNF-\u03b1 may correlate with activity and severity of rheumatoid arthritis. Med. Sci. Monitor: Int. Med. J. Exp. Clin. Res. 21 (2015) 4030. 10.12659\/MSM.895116.","DOI":"10.12659\/MSM.895116"},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0395","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s13075-016-1197-5","article-title":"Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis","volume":"18","author":"Hull","year":"2016","journal-title":"Arthritis Res. Therapy"},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0400","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/cei.12335","article-title":"Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment","volume":"177","author":"Conigliaro","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cyto.2022.156007_b0405","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clim.2017.05.012","article-title":"Regulatory B cells in rheumatoid arthritis: alterations in patients receiving anti-TNF therapy","volume":"184","author":"Bank\u00f3","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cyto.2022.156007_b0410","doi-asserted-by":"crossref","unstructured":"E. Rodr\u00edguez-Mart\u00edn, I. Nieto-Ga\u00f1\u00e1n, Hern\u00e1ndez-Breijo et al., Blood lymphocyte subsets for early identification of non-remission to TNF inhibitors in rheumatoid arthritis, Front. Immunol. 11 (2020) 1913. 10.3389\/fimmu.2020.01913.","DOI":"10.3389\/fimmu.2020.01913"},{"issue":"7","key":"10.1016\/j.cyto.2022.156007_b0415","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1084\/jem.20151255","article-title":"Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF\u2013TNF-RII binding in rheumatoid arthritis","volume":"213","author":"Nguyen","year":"2016","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.cyto.2022.156007_b0420","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/jgh3.12259","article-title":"Regulatory T cells in Crohn's disease following anti-TNF-\u03b1 thBank\u00f3erapy","volume":"4","author":"Chiba","year":"2020","journal-title":"JGH Open"},{"issue":"3","key":"10.1016\/j.cyto.2022.156007_b0425","article-title":"Polarization of rheumatoid macrophages by TNF targeting through an IL-10\/STAT3 mechanism","volume":"10","author":"Degbo\u00e9","year":"2019","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2022.156007_b0430","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/gutjnl-2019-318264","article-title":"Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling","volume":"69","author":"Koelink","year":"2020","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cyto.2022.156007_b0435","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-015-0016-9","article-title":"Rituximab for rheumatoid arthritis","volume":"2","author":"Cohen","year":"2015","journal-title":"Rheumatol. Therapy"},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0440","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/bcp.12916","article-title":"A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis","volume":"82","author":"Cohen","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.cyto.2022.156007_b0445","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/BOR.0000000000000272","article-title":"Suppression of normal immune responses after treatment with rituximab","volume":"28","author":"Kado","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.cyto.2022.156007_b0450","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofman","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2022.156007_b0455","article-title":"A link between B cells and bone erosion in rheumatoid arthritis: receptor activator of nuclear factor kappa-B ligand production by memory B cells. Arthritis","author":"Meednu","year":"2015","journal-title":"Rheumatol"},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0460","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/annrheumdis-2014-206015","article-title":"MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study","volume":"75","author":"Peterfy","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2022.156007_b0465","doi-asserted-by":"crossref","unstructured":"L. Garcia-Montoya, C. Villota-Eraso, M.Y.M. Yusof, E.M. Vital, P. Emery, Lessons for rituximab therapy in patients with rheumatoid arthritis, Lancet Rheumatol. (2020). 10.1016\/S2665-9913(20)30033-3.","DOI":"10.1016\/S2665-9913(20)30033-3"},{"key":"10.1016\/j.cyto.2022.156007_b0470","doi-asserted-by":"crossref","DOI":"10.1111\/imr.12859","article-title":"The role of B cell antigen presentation in the initiation of CD4+ T cell response","author":"Hua","year":"2020","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.cyto.2022.156007_b0475","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/imm.12212","article-title":"Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis","volume":"142","author":"D\u00edaz-Torn\u00e9","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.cyto.2022.156007_b0480","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/751793","article-title":"Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications","volume":"2015","author":"Alunno","year":"2015","journal-title":"Mediators Inflamm."},{"issue":"12","key":"10.1016\/j.cyto.2022.156007_b0485","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1002\/art.24998","article-title":"Depletion of functionally active CD20+ T cells by rituximab treatment","volume":"60","author":"Wilk","year":"2009","journal-title":"Arthritis & Rheumatism: Official Journal of the American College of Rheumatology"},{"issue":"3","key":"10.1016\/j.cyto.2022.156007_b0490","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/cei.12771","article-title":"Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sj\u00f6gren's syndrome: a pilot study","volume":"184","author":"Alunno","year":"2016","journal-title":"Clin. Exp. Immunol."},{"issue":"8","key":"10.1016\/j.cyto.2022.156007_b0495","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00296-016-3480-9","article-title":"Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials","volume":"36","author":"Kunwar","year":"2016","journal-title":"Rheumatol. Int."},{"issue":"3","key":"10.1016\/j.cyto.2022.156007_b0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.11144\/Javeriana.umed59-3.cyto","article-title":"Comparison of plasma cytokine levels before and after treatment with rituximab in patients with rheumatoid arthritis and systemic lupus erythematosus-associated polyautoimmunity","volume":"59","author":"Barahona Correa","year":"2018","journal-title":"Universitas M\u00e9dica"},{"issue":"5","key":"10.1016\/j.cyto.2022.156007_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101106","article-title":"ROR\u03b3t-driven TH17 cell differentiation requires epigenetic control by the Swi\/Snf chromatin remodeling complex","volume":"23","author":"Lee","year":"2020","journal-title":"Iscience"},{"issue":"10","key":"10.1016\/j.cyto.2022.156007_b0510","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1084\/jem.20141030","article-title":"Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity","volume":"212","author":"Paterson","year":"2015","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.cyto.2022.156007_b0515","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1073\/pnas.1812186116","article-title":"Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti\u2013CTLA-4 antibody","volume":"116","author":"Ha","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.cyto.2022.156007_b0520","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/ni.2870","article-title":"New inhibitory signaling by CTLA-4","volume":"15","author":"Wulfing","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2022.156007_b0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-020-2138-x","article-title":"Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells","volume":"22","author":"Liu","year":"2020","journal-title":"Arthritis research & therapy"},{"issue":"3","key":"10.1016\/j.cyto.2022.156007_b0530","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/cei.12367","article-title":"Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-\u03b1 agents","volume":"177","author":"Picchianti Diamanti","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2022.156007_b0535","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/rheumatology\/kev403","article-title":"Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis","volume":"55","author":"Bonelli","year":"2016","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.cyto.2022.156007_b0540","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12016-017-8603-x","article-title":"Memory B cells and response to abatacept in rheumatoid arthritis","volume":"53","author":"Gazeau","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.cyto.2022.156007_b0545","doi-asserted-by":"crossref","unstructured":"ESENSTEN, H. Jonathan, et al. CD28 costimulation: from mechanism to therapy, Immunity, 44 (5) (2016) 973-988. 10.1016\/j.immuni.2016.04.020.","DOI":"10.1016\/j.immuni.2016.04.020"},{"key":"10.1016\/j.cyto.2022.156007_b0550","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaut.2019.04.016","article-title":"Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells","volume":"101","author":"Lorenzetti","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cyto.2022.156007_b0555","doi-asserted-by":"crossref","unstructured":"A. Bozec, Y. Luo, C. Engdahl, C. Figueiredo, H. Bang, G. Schett, et al., Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner, Arthrit. Res. Therapy 20 (1) (2018) 1-9. A. Alunno, F. Carubbi, O. Bistoni, et al., Interleukin (IL)\u201017\u2010producing pathogenic T lymphocytes co\u2010express CD20 and are depleted by rituximab in primary Sj\u00f6gren's syndrome: a pilot study, Clin. Exp. Immunol. 184 (3) (2016) 284-292. 10.1186\/s13075-018-1527-x.","DOI":"10.1186\/s13075-018-1527-x"},{"issue":"12","key":"10.1016\/j.cyto.2022.156007_b0560","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","article-title":"The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2022.156007_b0565","doi-asserted-by":"crossref","unstructured":"Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology, 2019: 58 (1): i43-i54. 10.1093\/rheumatology\/key276.","DOI":"10.1093\/rheumatology\/key276"},{"key":"10.1016\/j.cyto.2022.156007_b0570","first-page":"1","article-title":"JAK inhibitors for the treatment of rheumatoid arthritis","author":"Morinobu","year":"2020","journal-title":"Immunol. Med."},{"key":"10.1016\/j.cyto.2022.156007_b0575","doi-asserted-by":"crossref","unstructured":"Y. Fujita, N. Matsuoka, J. Temmoku, et al., JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells, 2020. 10.1186\/s12865-020-00365-w.","DOI":"10.21203\/rs.3.rs-17287\/v1"},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0580","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40744-019-00192-5","article-title":"Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials","volume":"7","author":"Tarrant","year":"2020","journal-title":"Rheumatol. Therapy"},{"key":"10.1016\/j.cyto.2022.156007_b0585","article-title":"Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors","author":"Meyer","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2022.156007_b0590","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3389\/fimmu.2019.00541","article-title":"Targeting activated synovial fibroblasts in rheumatoid arthritis by peficitinib","volume":"10","author":"Diller","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2022.156007_b0595","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fmed.2018.00039","article-title":"Tools for the assessment of comorbidity burden in rheumatoid arthritis","volume":"5","author":"Aslam","year":"2018","journal-title":"Front. Med."},{"issue":"7","key":"10.1016\/j.cyto.2022.156007_b0600","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.autrev.2019.05.007","article-title":"Challenges in the treatment of rheumatoid arthritis","volume":"18","author":"Conigliaro","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.cyto.2022.156007_b0605","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10067-016-3528-y","article-title":"Factors influencing the choice of first-and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry","volume":"36","author":"Monti","year":"2017","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0610","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13075-018-1645-5","article-title":"Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)","volume":"20","author":"Sergeant","year":"2018","journal-title":"Arthrit. Res. Therapy"},{"issue":"4","key":"10.1016\/j.cyto.2022.156007_b0615","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/annrheumdis-2013-204078","article-title":"Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study","volume":"74","author":"M\u00f6ller","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.cyto.2022.156007_b0620","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/pds.4555","article-title":"Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis","volume":"27","author":"Svanstr\u00f6m","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.cyto.2022.156007_b0625","doi-asserted-by":"crossref","first-page":"e22513","DOI":"10.1002\/jbt.22513","article-title":"Association between SLCO1A2 genetic variation and methotrexate toxicity in human rheumatoid arthritis treatment","author":"Wang","year":"2020","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"5","key":"10.1016\/j.cyto.2022.156007_b0630","first-page":"862","article-title":"Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review","volume":"37","author":"Doria","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"issue":"24","key":"10.1016\/j.cyto.2022.156007_b0635","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2146\/ajhp050514","article-title":"Treatment of rheumatoid arthritis","volume":"63","author":"Gaffo","year":"2006","journal-title":"Am. J. Health-system Pharm."},{"issue":"4","key":"10.1016\/j.cyto.2022.156007_b0640","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40744-019-00177-4","article-title":"Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis","volume":"6","author":"Reed","year":"2019","journal-title":"Rheumatol. Therapy"},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0645","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/rheumatology\/key275","article-title":"The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients","volume":"58","author":"Schapink","year":"2019","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.cyto.2022.156007_b0650","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/art.41299","article-title":"Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis","volume":"72","author":"Boyapati","year":"2020","journal-title":"Arthrit. Rheumatol."},{"key":"10.1016\/j.cyto.2022.156007_b0655","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jconrel.2020.11.041","article-title":"RNA interference-mediated suppression of TNF-\u03b1 converting enzyme as an alternative anti-TNF-\u03b1 therapy for rheumatoid arthritis","volume":"330","author":"Song","year":"2021","journal-title":"J. Control. Release"},{"issue":"16","key":"10.1016\/j.cyto.2022.156007_b0660","doi-asserted-by":"crossref","first-page":"2100098","DOI":"10.1002\/adma.202100098","article-title":"Significantly Improving the Bioefficacy for Rheumatoid Arthritis with Supramolecular Nanoformulations","volume":"33","author":"Ma","year":"2021","journal-title":"Adv. Mater."},{"issue":"6","key":"10.1016\/j.cyto.2022.156007_b0665","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/adhm.201901541","article-title":"Recent Advances in Nanotheranostics for Treat-to-Target of Rheumatoid Arthritis","volume":"9","author":"Wang","year":"2020","journal-title":"Adv. Healthcare Mater."},{"issue":"5","key":"10.1016\/j.cyto.2022.156007_b0670","first-page":"2","article-title":"Biomarkers in Rheumatoid Arthritis","volume":"13","author":"Shapiro","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.cyto.2022.156007_b0675","first-page":"144","article-title":"Biomarkers in rheumatoid arthritis, what is new?","volume":"9","author":"Gavril\u0103","year":"2016","journal-title":"J. Med. Life"},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0680","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jare.2015.01.008","article-title":"Identification of rheumatoid arthritis biomarkers based on single nucleotide polymorphisms and haplotype blocks: a systematic review and meta-analysis","volume":"7","author":"Saad","year":"2016","journal-title":"J. Adv. Res."},{"issue":"5","key":"10.1016\/j.cyto.2022.156007_b0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9051555","article-title":"Interleukin-15 as a biomarker candidate of rheumatoid arthritis development","volume":"9","author":"Kurowska","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.cyto.2022.156007_b0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cti2.1237","article-title":"Rheumatoid arthritis CD14+ monocytes display metabolic and inflammatory dysfunction, a phenotype that precedes clinical manifestation of disease","volume":"10","author":"McGarry","year":"2021","journal-title":"Clin. Transl. Immunol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466622002162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466622002162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:46:15Z","timestamp":1760910375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466622002162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":138,"alternative-id":["S1043466622002162"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2022.156007","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune hallmarks of rheumatoid arthritis management: A brief review","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2022.156007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156007"}}